quantitative assessment of wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia
Authors
abstract
background: the wilms tumor 1 (wt1) gene is originally defined as a tumor suppressor gene and a transcription factor that overexpressed in leukemic cells. it is highly expressed in more than 80% of acute myeloid leukemia (aml) patients, both in bone marrow (bm) and in peripheral blood (pb), and it is used as a powerful and independent marker of minimal residual disease (mrd);we have determined the expression levels of the wt1 by real-time quantitative polymerase chain reaction (rq-pcr) in pb and bm in 126 newly diagnosed aml patients. materials and methods: this study was done in molecular pathology and cancer research center from april 2014 to june 2015, rq-pcr method was used to determine the wt1 gene expression in bm and/or pb samples from 126 patients of aml, we cloned both wt1 and abl genes for creating a standard curve, and we calculate copy number of wt1 genes in patients. results: a total of 126 aml patients consist of 70 males (55.6%) and 56 females (44.4%), with a median age of 26 years; 104 (81%) patients out of 126 show overexpression of wt1 gene. we also concomitant monitoring of fusion transcripts (pml rara, aml1-eto, mll-mll, cbfb-myh11, or dek-can) in our patients, the aml1-eto group showing remarkably low levels of wt1 compared with other fusion transcript and the cbfb-myh11 showing high levels of wt1. conclusion: we conclude that wt1 expression by rq-pcr in aml patients may be employed as an independent tool to detect mrd in the majority of normal karyotype aml patients.
similar resources
Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia
BACKGROUND The Wilms tumor 1 (WT1) gene is originally defined as a tumor suppressor gene and a transcription factor that overexpressed in leukemic cells. It is highly expressed in more than 80% of acute myeloid leukemia (AML) patients, both in bone marrow (BM) and in peripheral blood (PB), and it is used as a powerful and independent marker of minimal residual disease (MRD); we have determined ...
full textQuantitative Assessment of WT1 Expression by Real Time Quantitative PCR in Pediatric Patients with Acute Myeloblastic Leukemia
Background: Acute myeloid leukemia (AML) is one of myeloid malignancies which the risk increases with age increment. It is categorized based on genetic aberrations. Some of these genetic disorders can determine minimal residual diseases (MRD) and prognosis of AML patients. Wilms tumor (WT1) over expression is found in AML patients. The aim of this study was to determine the frequency of WT1 ove...
full textquantitative assessment of wt1 expression by real time quantitative pcr in pediatric patients with acute myeloblastic leukemia
increment. it is categorized based on genetic aberrations. some of these genetic disorders can determine minimal residual diseases (mrd) and prognosis of aml patients. wilms tumor (wt1) over expression is found in aml patients. the aim of this study was to determine the frequency of wt1 over expression in aml pediatric cases in north -east of iran. materials and methods: this retrospective stud...
full textOver-expression of Wilm’s Tumor Gene 1 (WT1) in Iranian Patients with Acute Myeloblastic Leukemia
Background: The Wilm’s tumor gene 1 (WT1) encodes a zinc finger transcription factor that is inactivated in a subset of Wilm’s tumors. It plays a crucial role in growth, proliferation and development of some embryonic and adult organs. WT1 is expressed as a tumor associated antigen (TAA) in various types of solid and hematopoietic malignancies and can be employed as a useful marker for targeted...
full textQuantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction.
We have developed a real-time quantitative polymerase chain reaction (PCR) assay using TaqMan technology (Applied Biosystems, Foster City, CA) for monitoring donor cell engraftment in allogenic hematopoietic stem cell transplant recipients. For this purpose, we selected 19 specific sequence polymorphisms belonging to 11 human biallelic loci located on 9 different chromosomes. Using a set of spe...
full textMy Resources
Save resource for easier access later
Journal title:
journal of research in medical sciencesجلد ۲۲، شماره ۱، صفحات ۰-۰
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023